Cost-Effectiveness of First-Line Pembrolizumab Monotherapy Versus Chemotherapy in High Programmed Death-Ligand 1 Advanced Non–Small Cell Lung Cancer in the Irish Healthcare Setting

Ryan Wong Chu, Antonio Vegas García, Conor Hickey,Derek Gerard Power,Claire Gorry

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research（2023）

引用 2|浏览4

暂无评分

摘要

At the current list price, first-line pembrolizumab monotherapy is not considered cost-effective for the treatment of advanced PD-L1 TPS ≥ 50% NSCLC in the Irish healthcare setting.

查看译文

关键词

cost-effectiveness analysis,economic evaluation,health technology assessment,immunotherapy,non–small cell lung cancer,Ireland

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要